The estimated Net Worth of John Schembri is at least $103 Tausend dollars as of 17 August 2015. John Schembri owns over 1,500 units of Global Blood Therapeutics stock worth over $102,735 and over the last 9 years John sold GBT stock worth over $0.
John has made over 1 trades of the Global Blood Therapeutics stock since 2015, according to the Form 4 filled with the SEC. Most recently John bought 1,500 units of GBT stock worth $32,355 on 17 August 2015.
The largest trade John's ever made was buying 1,500 units of Global Blood Therapeutics stock on 17 August 2015 worth over $32,355. On average, John trades about 500 units every 0 days since 2015. As of 17 August 2015 John still owns at least 1,500 units of Global Blood Therapeutics stock.
You can see the complete history of John Schembri stock trades at the bottom of the page.
John's mailing address filed with the SEC is C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT, SUITE 101, SOUTH SAN FRANCISCO, CA, 94080.
Over the last 9 years, insiders at Global Blood Therapeutics have traded over $164,753,446 worth of Global Blood Therapeutics stock and bought 255,000 units worth $8,595,265 . The most active insiders traders include Advisors Llcperceptive Life..., Rock Ventures Ii, L.P.Third... und Kevin P Starr. On average, Global Blood Therapeutics executives and independent directors trade stock every 14 days with the average trade being worth of $3,133,144. The most recent stock trade was executed by Nazila Habibizad on 1 October 2022, trading 1,557 units of GBT stock currently worth $106,639.
Global Blood Therapeutics (GBT) is a biopharmaceutical company dedicated to the discovery, development, and delivery of life-changing treatments that provide hope to underserved patient communities. Founded in 2011, GBT is delivering on its goal to transform the treatment and care of sickle cell disease (SCD), a lifelong, devastating inherited blood disorder. The company has introduced Oxbryta® (voxelotor) tablets, the first FDA-approved treatment that directly inhibits sickle hemoglobin polymerization, the root cause of red blood cell sickling in SCD. GBT is also advancing its pipeline program in SCD with inclacumab, a P-selectin inhibitor in development to address pain crises associated with the disease, and GBT021601 (GBT601), the company's next generation hemoglobin S polymerization inhibitor. In addition, GBT's drug discovery teams are working on new targets to develop the next wave of treatments for SCD.
Global Blood Therapeutics executives and other stock owners filed with the SEC include: